Literature DB >> 16918946

The role of chromogranin A in the management of patients with phaeochromocytoma.

Erika Grossrubatscher1, Paolo Dalino, Federico Vignati, Marcello Gambacorta, Raffaele Pugliese, Marco Boniardi, Ornella Rossetti, Alessandro Marocchi, Michaela Bertuzzi, Paola Loli.   

Abstract

OBJECTIVE: Chromogranin A (CgA) is the most accurate general marker of neuroendocrine tumours. Supranormal CgA concentrations have been recorded in patients with tumours of neuroectodermal origin such as phaeochromocytoma and paraganglioma.
DESIGN: The present study was performed to assess the role of CgA determination in the management of patients with phaeochromocytoma, in comparison with urinary catecholamines and their metabolites. PATIENTS: The patients studied included 22 cases with phaeochromocytoma at initial presentation or at relapse some years after surgical cure or during follow-up of a malignant phaeochromocytoma. Seventeen patients were evaluated before and after surgical removal of phaeochromocytoma. To assess the specificity of the hormonal parameters, 20 subjects were enrolled as controls; they were from a group of patients referred to our observation for possible phaeochromocytoma and who were subsequently proven not to have the disease.
RESULTS: Urinary epinephrine and norepinephrine were supranormal in 82% and 77% of patients, respectively. Urinary metanephrines and normetanephrines were supranormal in 84% and 89% of patients, respectively. The combination of urinary metanephrine and normetanephrine had a sensitivity of 100% in identifying a phaeochromocytoma. CgA was supranormal in 91% of patients. Combining the results of CgA and urinary catecholamines (epinephrine and norepinephrine), the sensitivity for diagnosis of phaeochromocytoma was 100%. Urinary catecholamines, metabolites (metanephrine and normetanephrine) and CgA levels in patients with malignant phaeochromocytoma did not differ significantly from those of patients with benign lesions. In most cases, CgA normalized after surgery.
CONCLUSIONS: Our results indicate that CgA is a good marker of phaeochromocytoma; measurement of CgA could have a role in the follow-up of patients operated on for phaeochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918946     DOI: 10.1111/j.1365-2265.2006.02591.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

Review 1.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

Review 2.  Autonomic nervous system and cancer.

Authors:  Marta Simó; Xavier Navarro; Victor J Yuste; Jordi Bruna
Journal:  Clin Auton Res       Date:  2018-03-28       Impact factor: 4.435

3.  A Rare Case of Adrenal Pheochromocytoma with Unusual Clinical and Biochemical Presentation: 
A Case Report and Literature Review.

Authors:  Waad-Allah S Mula-Abed; Riyaz Ahmed; Fatima A Ramadhan; Manal K Al-Kindi; Noor B Al-Busaidi; Hilal N Al-Muslahi; Mohammad A Al-Lamki
Journal:  Oman Med J       Date:  2015-09

4.  Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center.

Authors:  Auryan Szalat; Merav Fraenkel; Victoria Doviner; Asher Salmon; David J Gross
Journal:  Endocrine       Date:  2010-11-11       Impact factor: 3.633

5.  Diagnosis of pheochromocytoma in the setting of Parkinson disease.

Authors:  Shyamal H Mehta; Rajan Prakash; L Michael Prisant; Carlos M Isales; John C Morgan; Hadyn Williams; Kapil D Sethi
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

6.  Advances in biochemical screening for phaeochromocytoma using biogenic amines.

Authors:  Malcolm J Whiting; Matthew P Doogue
Journal:  Clin Biochem Rev       Date:  2009-02

7.  Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma.

Authors:  Alicia Algeciras-Schimnich; Carol M Preissner; William F Young; Ravinder J Singh; Stefan K G Grebe
Journal:  J Clin Endocrinol Metab       Date:  2007-10-16       Impact factor: 5.958

Review 8.  Treatment of malignant pheochromocytoma.

Authors:  R Adjallé; P F Plouin; K Pacak; H Lehnert
Journal:  Horm Metab Res       Date:  2009-08-11       Impact factor: 2.936

9.  PREDICTIVE VALUE OF CHROMOGRANIN A IN A DIAGNOSIS TOWARDS PHEOCHROMOCYTOMA IN ADRENAL INCIDENTALOMA.

Authors:  S K Zawadzka-Leska; M Radziszewski; K Malec; A Stadnik; U Ambroziak
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

10.  Catecholamine-secreting carotid body paraganglioma: successful preoperative control of hypertension and clinical symptoms using high-dose long-acting octreotide.

Authors:  Omayma Elshafie; Yahya Al Badaai; Khalifa Alwahaibi; Asim Qureshi; Samir Hussein; Faisal Al Azzri; Ali Almamari; Ncholas Woodhouse
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.